qsymia and Overweight
qsymia has been researched along with Overweight* in 4 studies
Other Studies
4 other study(ies) available for qsymia and Overweight
Article | Year |
---|---|
Therapies for obesity and medication-associated weight gain.
Compared to the general population, individuals with psychiatric illness, especially serious and chronic mood and psychotic disorders, are more likely to be overweight or obese, have higher rates of weight-related medical conditions, and have greater non-suicide mortality rates. Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use. Bariatric surgery is an effective approach for morbid obesity, but careful psychiatric assessment before and follow up after surgery is necessary. Behavioral lifestyle interventions to promote weight loss are effective and should be implemented along with or instead of drug therapies or surgery. Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic | 2013 |
New medications for weight loss.
Topics: Appetite Depressants; Benzazepines; Drug Combinations; Fructose; Humans; Obesity; Overweight; Phentermine; Weight Loss | 2012 |
2 new drugs for weight loss.
Topics: Anti-Obesity Agents; Benzazepines; Drug Combinations; Drug Interactions; Fructose; Humans; Obesity; Overweight; Phentermine; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Weight Loss | 2012 |
ACS chemical neuroscience molecule spotlight on Qnexa.
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission. Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials, Phase III as Topic; Comorbidity; Double-Blind Method; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Overweight; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Treatment Outcome; United States; United States Food and Drug Administration; Weight Loss | 2011 |